138 related articles for article (PubMed ID: 14678960)
1. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival.
Berger AJ; Kluger HM; Li N; Kielhorn E; Halaban R; Ronai Z; Rimm DL
Cancer Res; 2003 Dec; 63(23):8103-7. PubMed ID: 14678960
[TBL] [Abstract][Full Text] [Related]
2. Expression of the ets-1 proto-oncogene in melanocytic lesions.
Keehn CA; Smoller BR; Morgan MB
Mod Pathol; 2003 Aug; 16(8):772-7. PubMed ID: 12920221
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
4. Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction.
Berger AJ; Davis DW; Tellez C; Prieto VG; Gershenwald JE; Johnson MM; Rimm DL; Bar-Eli M
Cancer Res; 2005 Dec; 65(23):11185-92. PubMed ID: 16322269
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of nuclear ING3 expression in human cutaneous melanoma.
Wang Y; Dai DL; Martinka M; Li G
Clin Cancer Res; 2007 Jul; 13(14):4111-6. PubMed ID: 17634537
[TBL] [Abstract][Full Text] [Related]
6. Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma.
Divito KA; Berger AJ; Camp RL; Dolled-Filhart M; Rimm DL; Kluger HM
Cancer Res; 2004 Dec; 64(23):8773-7. PubMed ID: 15574790
[TBL] [Abstract][Full Text] [Related]
7. ATF2 confers radiation resistance to human melanoma cells.
Ronai Z; Yang YM; Fuchs SY; Adler V; Sardana M; Herlyn M
Oncogene; 1998 Jan; 16(4):523-31. PubMed ID: 9484842
[TBL] [Abstract][Full Text] [Related]
8. Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma.
Chua R; Setzer S; Govindarajan B; Sexton D; Cohen C; Arbiser JL
J Am Acad Dermatol; 2009 May; 60(5):758-66. PubMed ID: 19389518
[TBL] [Abstract][Full Text] [Related]
9. Expression and prognostic value of activating transcription factor 2 (ATF2) and its phosphorylated form in mammary carcinomas.
Knippen S; Löning T; Müller V; Schröder C; Jänicke F; Milde-Langosch K
Anticancer Res; 2009 Jan; 29(1):183-9. PubMed ID: 19331149
[TBL] [Abstract][Full Text] [Related]
10. Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients.
Quaglino P; Osella-Abate S; Cappello N; Ortoncelli M; Nardò T; Fierro MT; Cavallo F; Savoia P; Bernengo MG
Melanoma Res; 2007 Apr; 17(2):75-82. PubMed ID: 17496782
[TBL] [Abstract][Full Text] [Related]
11. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma.
Scala S; Ottaiano A; Ascierto PA; Cavalli M; Simeone E; Giuliano P; Napolitano M; Franco R; Botti G; Castello G
Clin Cancer Res; 2005 Mar; 11(5):1835-41. PubMed ID: 15756007
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma.
Prieto VG; Mourad-Zeidan AA; Melnikova V; Johnson MM; Lopez A; Diwan AH; Lazar AJ; Shen SS; Zhang PS; Reed JA; Gershenwald JE; Raz A; Bar-Eli M
Clin Cancer Res; 2006 Nov; 12(22):6709-15. PubMed ID: 17121890
[TBL] [Abstract][Full Text] [Related]
13. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
14. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
Kramer C; Klasmeyer K; Bojar H; Schulz WA; Ackermann R; Grimm MO
Cancer; 2007 May; 109(10):2016-24. PubMed ID: 17394193
[TBL] [Abstract][Full Text] [Related]
15. Activating transcription factor 2 in mesenchymal tumors.
Endo M; Su L; Nielsen TO
Hum Pathol; 2014 Feb; 45(2):276-84. PubMed ID: 24289970
[TBL] [Abstract][Full Text] [Related]
16. Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response.
Ugurel S; Houben R; Schrama D; Voigt H; Zapatka M; Schadendorf D; Bröcker EB; Becker JC
Clin Cancer Res; 2007 Nov; 13(21):6344-50. PubMed ID: 17975146
[TBL] [Abstract][Full Text] [Related]
17. Comparison of metallothionein-overexpression with sentinel lymph node biopsy as prognostic factors in melanoma.
Weinlich G; Topar G; Eisendle K; Fritsch PO; Zelger B
J Eur Acad Dermatol Venereol; 2007 May; 21(5):669-77. PubMed ID: 17447982
[TBL] [Abstract][Full Text] [Related]
18. Novel role for RGS1 in melanoma progression.
Rangel J; Nosrati M; Leong SP; Haqq C; Miller JR; Sagebiel RW; Kashani-Sabet M
Am J Surg Pathol; 2008 Aug; 32(8):1207-12. PubMed ID: 18580492
[TBL] [Abstract][Full Text] [Related]
19. Activating transcription factor 2 expression in the adult human brain: association with both neurodegeneration and neurogenesis.
Pearson AG; Curtis MA; Waldvogel HJ; Faull RL; Dragunow M
Neuroscience; 2005; 133(2):437-51. PubMed ID: 15878807
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of P-cadherin expression in melanocytic skin tumours analysed by high-throughput tissue microarrays.
Bauer R; Wild PJ; Meyer S; Bataille F; Pauer A; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
J Clin Pathol; 2006 Jul; 59(7):699-705. PubMed ID: 16565225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
